Answers are grounded in this paper and cite their sources.
In patients with compensated cirrhosis caused by MASH, efruxifermin did not significantly reduce fibrosis at 36 weeks. (Funded by Akero Therapeutics; SYMMETRY ClinicalTrials.gov number, NCT05039450.).
No takes yet. Share an insight, caveat, or question.
Noureddin et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: